Guideline for Evaluation and Management of Chronic Cough in Adults

Assessment and Initial Evaluation

• Obtain a chest radiograph and spirometry with bronchodilator reversibility as mandatory baseline investigations for any adult with cough lasting > 8 weeks (Chest guideline) 1.
• Quantify cough severity and its impact on quality of life with a validated tool before starting treatment (Thorax guideline) 1.
• Define chronic cough as a cough persisting for more than 8 weeks (Thorax guideline) 1.
• Review current medications and discontinue ACE‑inhibitors or sitagliptin when present, as they can provoke cough (Chest guideline) 2.
• Screen for environmental and occupational exposures (tobacco smoke, workplace irritants, indoor allergens) (Chest guideline) 3.
• Ask about recent residence in East Asian countries (Japan, Korea, China) to consider diffuse panbronchiolitis (Chest guideline) 4.

Red‑Flag Symptoms Requiring Immediate Evaluation

• Hemoptysis (Chest guideline) 2.
• New or changed cough in smokers older than 45 years (Chest guideline) 2.
• Adults aged 55–80 years with a ≥30‑pack‑year smoking history (Chest guideline) 2.
• Prominent dyspnea at rest or nocturnal dyspnea (Chest guideline) 2.
• Hoarseness (Chest guideline) 2.
• Systemic signs such as fever, unintended weight loss, or peripheral edema (Chest guideline) 2.
• Dysphagia (trouble swallowing) or recurrent pneumonia (Chest guideline) 2.

Additional Diagnostic Testing Based on Clinical Suspicion

• Bronchial hyperresponsiveness testing (e.g., methacholine challenge) when asthma is suspected but spirometry is normal (Chest guideline) 5.
• Assessment of eosinophilic airway inflammation (sputum eosinophils or exhaled nitric oxide) to identify non‑asthmatic eosinophilic bronchitis (NAEB) (Chest guideline) 5.

Management of the Three Most Common Causes

Upper Airway Cough Syndrome (UACS) – Most Common Etiology

• Trial a topical nasal corticosteroid for 1 month in patients with prominent nasal symptoms (Thorax guideline) 6.
• Consider a first‑generation antihistamine/decongestant combination; evidence for second‑generation agents is conflicting (Thorax guideline) 6.

Asthma – Second Most Common Etiology

• Conduct a 2‑week oral corticosteroid trial to determine responsiveness; a positive response supports continuation with inhaled corticosteroids (Thorax guideline) 1.
• Initiate inhaled corticosteroids when the oral steroid trial is positive (Chest guideline) 7.
• Avoid inhaled corticosteroids if bronchial hyperresponsiveness testing and eosinophilic inflammation are both negative (Chest guideline) 5.

Gastro‑Esophageal Reflux Disease (GERD) – Third Most Common Etiology

• Prescribe intensive acid suppression with a proton‑pump inhibitor for at least 2 months; shorter courses are ineffective (Thorax guideline) 1.
• Add a prokinetic agent (e.g., metoclopramide) in selected patients who do not respond adequately to PPIs (Thorax guideline) 6.
• Do not prescribe PPIs if objective work‑up for acid reflux is negative (Chest guideline) 5.

Non‑Asthmatic Eosinophilic Bronchitis (NAEB)

• Recognize that NAEB accounts for roughly 10–30 % of specialist referrals for chronic cough (Chest guideline) 7.
• Confirm eosinophilic airway inflammation without bronchial hyperresponsiveness before treatment (Chest guideline) 7.
• Treat confirmed NAEB with inhaled or oral corticosteroids (Chest guideline) 7.

Follow‑Up and Reassessment

• Re‑measure cough severity with the same validated instrument to objectively assess treatment effect (Thorax guideline) 1.
• Schedule a follow‑up visit (in‑person or telephone) 4–6 weeks after the initial evaluation (Chest guideline) 2.
• If cough persists, arrange further follow‑up and proceed to the next sequential therapeutic trial (Chest guideline) 2.

Management of Refractory (Unexplained) Chronic Cough

• Refer patients with refractory cough to a recognized cough clinic after completing guideline‑based trials (Chest guideline) 2.
• Offer multimodality speech‑pathology therapy as the primary non‑pharmacologic intervention (Chest guideline) 5.
• Consider a gabapentin trial (starting 300 mg once daily, titrating up to 1,800 mg/day as tolerated) after discussing potential side effects and obtaining informed consent (Chest guideline) 5.
• Re‑evaluate the risk‑benefit profile of gabapentin at 6 months before continuation (Chest guideline) 5.

Special Considerations for Allergists

• Use allergy skin testing to differentiate allergic from non‑allergic rhinitis when UACS is suspected (Allergy & Clinical Immunology guideline) 3.
• Identify dust‑mite sensitization, which can contribute to both asthma and rhinitis‑related cough (Allergy & Clinical Immunology guideline) 3.
• Consider allergen immunotherapy for patients with documented IgE‑mediated sensitivity that appears to drive cough (Allergy & Clinical Immunology guideline) 3.
• Promptly diagnose and remove patients from occupational exposures that may be perpetuating cough (Allergy & Clinical Immunology guideline) 3.

Common Pitfalls to Avoid

• Do not label a cough lasting > 8 weeks as “post‑infectious” without further evaluation (Chest guideline) 4.
• Avoid prescribing antibiotics for post‑infectious cough in the absence of bacterial infection (Chest guideline) 4.
• Ensure proton‑pump inhibitor therapy is continued for a minimum of 2 months before judging efficacy (Thorax guideline) 1.
• Do not start inhaled corticosteroids empirically in unexplained cough without evidence of bronchial hyperresponsiveness or eosinophilia (Chest guideline) 5.
• Recognize that multiple etiologies (UACS, asthma, GERD) frequently coexist and may require combined treatment (Chest guideline) 2.

Epidemiology and Etiology of Chronic Cough

Primary Causes

• The American College of Chest Physicians (ACCP) identifies upper airway cough syndrome (UACS), asthma, gastro‑esophageal reflux disease (GERD), and non‑asthmatic eosinophilic bronchitis (NAEB) as the four conditions that together account for the overwhelming majority of chronic cough (> 8 weeks) in nonsmokers not receiving ACE‑inhibitors. 8
• UACS is the single most frequent cause worldwide, responsible for roughly 33 %–48 % of chronic cough presentations. 9
• UACS, formerly termed post‑nasal drip syndrome, may present as “silent PNDS,” where cough is the only symptom despite underlying rhinosinus disease. 10
• Asthma accounts for about 16 %–25 % of chronic cough cases; cough‑variant asthma can occur without wheeze, dyspnea, or other respiratory complaints. 9
• GERD is the third leading etiology and often manifests as “silent GERD,” lacking classic heartburn or regurgitation. 8
• NAEB contributes to 5 %–33 % of chronic cough cases, with higher prevalence reported in studies outside the United States. It is characterized by eosinophilic airway inflammation, normal spirometry, absence of bronchial hyper‑responsiveness, and a favorable response to corticosteroids. 11

Co‑existing Etiologies

• In 92 %–100 % of nonsmoking patients not on ACE‑inhibitors who have a normal chest radiograph, one or more of UACS, asthma, and GERD are present either alone or in combination, underscoring the need to evaluate and treat multiple causes simultaneously. 10

Medication‑Induced Causes

• ACE‑inhibitors precipitate chronic cough in a notable subset of patients; cessation of the drug typically leads to cough resolution within 1–4 weeks. 8
• The DPP‑4 inhibitor sitagliptin has also been implicated as a cause of chronic cough and should be discontinued during the initial work‑up. 8

Less Common but Clinically Relevant Causes

• Post‑infectious cough was reported in ≈48 % of sub‑acute cough series, although many experts consider these cases to represent persistent UACS, transient bronchial hyper‑responsiveness, or prolonged airway inflammation rather than a distinct entity. 11
• Outbreaks of Bordetella pertussis can produce chronic cough in localized epidemics. 10
• Chronic bronchitis/COPD accounts for 4 %–12 % of chronic cough cases, predominantly among current or former smokers. 12
• Rare causes include bronchiectasis, interstitial lung diseases, endobronchial abnormalities (e.g., tumors, tuberculosis, sarcoidosis), and thyroid disease. 10

Environmental and Occupational Factors

• Systematic assessment of environmental and occupational exposures—such as tobacco smoke, workplace irritants, indoor allergens, and particulate pollution—is essential because these factors may act as primary causes or perpetuating contributors to chronic cough. 8

Clinical Caveats

• The character, timing, or productivity of the cough does not provide diagnostic discrimination and should not be used to rule in or out specific etiologies. 10
• Even patients who produce noticeable sputum most often have an underlying UACS, asthma, or GERD rather than a distinct sputum‑producing disorder. 12
• In regions where tuberculosis is endemic, TB must be considered, yet UACS, asthma, NAEB, and GERD remain the predominant causes of chronic cough. 12
• The diagnostic algorithm should prioritize evaluation of the four common causes (UACS, asthma, GERD, NAEB) first, as this strategy yields the highest diagnostic success rate. 10
• NAEB warrants early consideration because it can be readily diagnosed via induced sputum eosinophil analysis and typically responds predictably to corticosteroid therapy. 10

Evidence‑Based Guidelines for Chronic Productive Cough

Etiology and Epidemiology

• In adults who do not smoke and are not taking ACE inhibitors, the four most common etiologies—upper airway cough syndrome (UACS), asthma, gastro‑esophageal reflux disease (GERD), and non‑asthmatic eosinophilic bronchitis (NAEB)—together explain 92 %–100 % of chronic productive cough cases. 13
• Non‑asthmatic eosinophilic bronchitis is defined by eosinophilic airway inflammation with normal spirometry and absence of bronchial hyper‑responsiveness; diagnosis is confirmed by induced sputum eosinophil analysis, and the condition reliably improves with inhaled or oral corticosteroids. 13
• Early consideration of NAEB is recommended because it is straightforward to diagnose and treat, improving patient outcomes. 13

Post‑Infectious Cough (3–8 weeks)

• Most experts view post‑infectious cough as a continuation of upper airway cough syndrome, transient bronchial hyper‑responsiveness, or prolonged airway inflammation rather than a distinct disease entity. 13
• First‑line therapy for post‑infectious cough is inhaled ipratropium bromide; inhaled corticosteroids are added only if quality‑of‑life is markedly impaired and ipratropium alone fails. 13

Pertussis and Related Considerations

• Bordetella pertussis can act as a trigger in localized outbreaks and may sustain chronic cough by aggravating gastro‑esophageal reflux disease. 13

Rare but Important Causes

• Uncommon structural or neoplastic conditions that can produce chronic productive cough include endobronchial tumors, tuberculosis, sarcoidosis, retained foreign bodies, mediastinal masses, and tracheobronchopathia osteochondroplastica. 13

Diagnostic Approach

• After baseline chest radiography and spirometry, clinicians should systematically evaluate for UACS, asthma, GERD, and NAEB because these four conditions account for the overwhelming majority of chronic productive cough presentations. 13
• The character, timing, or productivity of the cough alone does not provide reliable diagnostic discrimination and should not be used to rule in or out specific etiologies. 13

Management Principles

• Empiric treatment targeting the most common causes—UACS, asthma, and GERD—should be initiated even when patients lack overt symptoms of those conditions (“silent” presentations). 13